Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck
Glenn J. Hanna(Dana-Farber Cancer Institute), Peter S. Hammerman(Broad Institute), Kwok‐Kin Wong(NYU Langone Health), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Ravindra Uppaluri(Brigham and Women's Hospital), Elena V. Ivanova(Massachusetts General Hospital), Patrick H. Lizotte(Harvard University), Alyssa F. Bacay(Dana-Farber Cancer Institute), Robert I. Haddad(Georgetown University), Hongye Liu(Dana-Farber Cancer Institute), Robert E. Jones(Beth Israel Deaconess Medical Center), Amanda J. Rode(Dana-Farber Cancer Institute), Mark Bittinger(Dana-Farber Cancer Institute), Megan E. Cavanaugh(Dana-Farber Cancer Institute), Nicole G. Chau(University of British Columbia), Jochen H. Lorch(Northwestern University)
Cited by 89
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k